Back to Directory

AuroraCell

Innate immunotherapy for fibrotic liver disease

AuroraCell is a biopharmaceutical company developing an innate immunotherapy for fibrotic liver disease. Its lead programme, Cytofinity, is at the preclinical proof-of-concept stage. The company is investigating whether the treatment could reduce fibrotic tissue and stimulate liver regeneration in patients with advanced cirrhosis. It envisages administering the therapy by infusion in a clinical setting if the programme progresses to human studies.